Enhertu Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer

Article Link: Enhertu Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer

TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE) January 15, 2021 — Daiichi Sankyo Company, Ltd.  (hereafter, Daiichi Sankyo) and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the…

Source: FDA New Drug Approvals